[1]Gao等，《A Pipeline to Call Multilevel Expression Changes between Cancer and Normal Tissues and Its Applications in Repurposing Drugs Effective for Gastric Cancer》.[2]Rudrapal, J. Khairnar和G. Jadhav, 《Drug Repurposing (DR)》.[3] Dudley, Deshpande 和Butte, 《Exploiting Drug-Disease Relationships for Computational Drug Repositioning》.[4] Rogers 和Hahn, 《Extended-Connectivity Fingerprints》.[5] Wang 等，《Ursolic Acid Inhibits Proliferation and Induces Apoptosis of Cancer Cells in Vitro and in Vivo》.[6] Chen, Li和Pan, 《Geldanamycin Induces Apoptosis in Human Gastric Carcinomas by Affecting Multiple Oncogenic Kinases That Have Synergic Effects with TNF-Related Apoptosis-Inducing Ligand》.[7]Liu等，《Parthenolide Increases the Sensitivity of Gastric Cancer Cells to Chemotherapy》.[8] Lee等，《Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatured gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.》[9] Kim等，《Tivantinib Inhibits the VEGF Signaling Pathway and Induces Apoptosis in Gastric Cancer Cells with C-MET or VEGFA Amplification》.[10]Yamasaki等，《MEK Inhibition Suppresses Metastatic Progression of KRAS-Mutated Gastric Cancer》.[11]Claerhout 等，《Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer》.